Endocrine-Related Cancer

References

1. ↵
   1. Ahmed S,
   2. Thomas G,
   3. Ghoussaini M,
   4. Healey CS,
   5. Humphreys MK,
   6. Platte R,
   7. Morrison J,
   8. Maranian M,
   9. Pooley KA,
   10. Luben R
   11. et al.

   2009 Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nature Genetics 41 585–590.
2. ↵
   1. Altucci L,
   2. Addeo R,
   3. Cicatiello L,
   4. Dauvois S,
   5. Parker MG,
   6. Truss M,
   7. Beato M,
   8. Sica V,
   9. Bresciani F &
   10. Weisz A

   1996 17β-Estradiol induces cyclin D1 gene transcription, p36D1–p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12 2315–2324.
3. ↵
   1. Anderson E

   2002 The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Research 4 197–201.
4. ↵
   1. Anzick SL,
   2. Kononen J,
   3. Walker RL,
   4. Azorsa DO,
   5. Tanner MM,
   6. Guan XY,
   7. Sauter G,
   8. Kallioniemi OP,
   9. Trent JM &
   10. Meltzer PS

   1997 AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277 965–968.
5. ↵
   1. Avantaggiati ML,
   2. Ogryzko V,
   3. Gardner K,
   4. Giordano A,
   5. Levine AS &
   6. Kelly K

   1997 Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89 1175–1184.
6. ↵
   1. Bahia H,
   2. Ashman JN,
   3. Cawkwell L,
   4. Lind M,
   5. Monson JR,
   6. Drew PJ &
   7. Greenman J

   2002 Karyotypic variation between independently cultured strains of the cell line MCF-7 identified by multicolour fluorescence in situ hybridization. International Journal of Oncology 20 489–494.
7. ↵
   1. Barkhem T,
   2. Haldosén LA,
   3. Gustafsson JA &
   4. Nilsson S

   2002 pS2 gene expression in HepG2 cells: complex regulation through crosstalk between the estrogen receptor α, an estrogen-responsive element, and the activator protein 1 response element. Molecular Pharmacology 61 1273–1283.
8. ↵
   1. Barski A,
   2. Cuddapah S,
   3. Cui K,
   4. Roh TY,
   5. Schones DE,
   6. Wang Z,
   7. Wei G,
   8. Chepelev I &
   9. Zhao K

   2007 High-resolution profiling of histone methylations in the human genome. Cell 129 823–837.
9. ↵
   1. Bauer UM,
   2. Daujat S,
   3. Nielsen SJ,
   4. Nightingale K &
   5. Kouzarides T

   2002 Methylation at arginine 17 of histone H3 is linked to gene activation. EMBO Reports 3 39–44.
10. ↵
    1. Baylin SB

    2005 DNA methylation and gene silencing in cancer. Nature Clinical Practice. Oncology 2 S4–S11.
11. ↵
    1. Belandia B,
    2. Orford RL,
    3. Hurst HC &
    4. Parker MG

    2002 Targeting of SWI/SNF chromatin remodelling complexes to estrogen-responsive genes. EMBO Journal 21 4094–4103.
12. ↵
    1. Bernstein BE,
    2. Kamal M,
    3. Lindblad-Toh K,
    4. Bekiranov S,
    5. Bailey DK,
    6. Huebert DJ,
    7. McMahon S,
    8. Karlsson EK,
    9. Kulbokas EJ,
    10. Gingeras TR
    11. et al.

    2005 Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 120 169–181.
13. ↵
    1. Bhat-Nakshatri P,
    2. Wang G,
    3. Appaiah H,
    4. Luktuke N,
    5. Carroll JS,
    6. Geistlinger TR,
    7. Brown M,
    8. Badve S,
    9. Liu Y &
    10. Nakshatri H

    2008 AKT alters genome-wide estrogen receptor α binding and impacts estrogen signaling in breast cancer. Molecular and Cellular Biology 28 7487–7503.
14. ↵
    1. Bourdeau V,
    2. Deschênes J,
    3. Métivier R,
    4. Nagai Y,
    5. Nguyen D,
    6. Bretschneider N,
    7. Gannon F,
    8. White JH &
    9. Mader S

    2004 Genome-wide identification of high-affinity estrogen response elements in human and mouse. Molecular Endocrinology 18 1411–1427.
15. ↵
    1. Brown AM,
    2. Jeltsch JM,
    3. Roberts M &
    4. Chambon P

    1984 Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. PNAS 81 6344–6348.
16. ↵
    1. Brzozowski AM,
    2. Pike AC,
    3. Dauter Z,
    4. Hubbard RE,
    5. Bonn T,
    6. Engström O,
    7. Ohman L,
    8. Greene GL,
    9. Gustafsson JA &
    10. Carlquist M

    1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 753–758.
17. ↵
    1. Buck MJ &
    2. Lieb JD

    2004 ChIP-chip: considerations for the design, analysis, and application of genome-wide chromatin immunoprecipitation experiments. Genomics 83 349–360.
18. ↵
    1. Bulyk ML

    2006 DNA microarray technologies for measuring protein–DNA interactions. Current Opinion in Biotechnology 17 422–430.
19. ↵
    1. Burdall SE,
    2. Hanby AM,
    3. Lansdown MR &
    4. Speirs V

    2003 Breast cancer cell lines: friend or foe? Breast Cancer Research 5 89–95.
20. ↵
    1. Carroll JS,
    2. Liu XS,
    3. Brodsky AS,
    4. Li W,
    5. Meyer CA,
    6. Szary AJ,
    7. Eeckhoute J,
    8. Shao W,
    9. Hestermann EV,
    10. Geistlinger TR
    11. et al.

    2005 Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122 33–43.
21. ↵
    1. Carroll JS,
    2. Meyer CA,
    3. Song J,
    4. Li W,
    5. Geistlinger TR,
    6. Eeckhoute J,
    7. Brodsky AS,
    8. Keeton EK,
    9. Fertuck KC,
    10. Hall GF
    11. et al.

    2006 Genome-wide analysis of estrogen receptor binding sites. Nature Genetics 38 1289–1297.
22. ↵
    1. Chakravarti D,
    2. LaMorte VJ,
    3. Nelson MC,
    4. Nakajima T,
    5. Schulman IG,
    6. Juguilon H,
    7. Montminy M &
    8. Evans RM

    1996 Role of CBP/P300 in nuclear receptor signalling. Nature 383 99–103.
23. ↵
    1. Chambon P,
    2. Dierich A,
    3. Gaub MP,
    4. Jakowlev S,
    5. Jongstra J,
    6. Krust A,
    7. LePennec JP,
    8. Oudet P &
    9. Reudelhuber T

    1984 Promoter elements of genes coding for proteins and modulation of transcription by estrogens and progesterone. Recent Progress in Hormone Research 40 1–42.
24. ↵
    1. Chanrion M,
    2. Negre V,
    3. Fontaine H,
    4. Salvetat N,
    5. Bibeau F,
    6. Grogan GM,
    7. Mauriac L,
    8. Katsaros D,
    9. Molina F,
    10. Theillet C
    11. et al.

    2008 A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clinical Cancer Research 14 1744–1752.
25. ↵
    1. Charpentier AH,
    2. Bednarek AK,
    3. Daniel RL,
    4. Hawkins KA,
    5. Laflin KJ,
    6. Gaddis S,
    7. MacLeod MC &
    8. Aldaz CM

    2000 Effects of estrogen on global gene expression: identification of novel targets of estrogen action. Cancer Research 60 5977–5983.
26. ↵
    1. Chen D,
    2. Ma H,
    3. Hong H,
    4. Koh SS,
    5. Huang SM,
    6. Schurter BT,
    7. Aswad DW &
    8. Stallcup MR

    1999 Regulation of transcription by a protein methyltransferase. Science 284 2174–2177.
27. ↵
    1. Chen D,
    2. Huang SM &
    3. Stallcup MR

    2000 Synergistic, p160 coactivator-dependent enhancement of estrogen receptor function by CARM1 and p300. Journal of Biological Chemistry 275 40810–40816.
28. ↵
    1. Cheng AS,
    2. Jin VX,
    3. Fan M,
    4. Smith LT,
    5. Liyanarachchi S,
    6. Yan PS,
    7. Leu YW,
    8. Chan MW,
    9. Plass C,
    10. Nephew KP
    11. et al.

    2006 Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-α responsive promoters. Molecular Cell 21 393–404.
29. ↵
    1. Coser KR,
    2. Chesnes J,
    3. Hur J,
    4. Ray S,
    5. Isselbacher KJ &
    6. Shioda T

    2003 Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray. PNAS 100 13994–13999.
30. ↵
    1. DeNardo DG,
    2. Kim HT,
    3. Hilsenbeck S,
    4. Cuba V,
    5. Tsimelzon A &
    6. Brown PH

    2005 Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. Molecular Endocrinology 19 362–378.
31. ↵
    1. Deschênes J,
    2. Bourdeau V,
    3. White JH &
    4. Mader S

    2007 Regulation of GREB1 transcription by estrogen receptor α through a multipartite enhancer spread over 20 kb of upstream flanking sequences. Journal of Biological Chemistry 282 17335–17339.
32. ↵
    1. DiRenzo J,
    2. Shang Y,
    3. Phelan M,
    4. Sif S,
    5. Myers M,
    6. Kingston R &
    7. Brown M

    2000 BRG-1 is recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation. Molecular and Cellular Biology 20 7541–7549.
33. ↵
    1. Dostie J,
    2. Richmond TA,
    3. Arnaout RA,
    4. Selzer RR,
    5. Lee WL,
    6. Honan TA,
    7. Rubio ED,
    8. Krumm A,
    9. Lamb J,
    10. Nusbaum C
    11. et al.

    2006 Chromosome conformation capture carbon copy (5C): a massively parallel solution for mapping interactions between genomic elements. Genome Research 16 1299–1309.
34. ↵
    1. Dubik D,
    2. Dembinski TC &
    3. Shiu RP

    1987 Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Research 47 6517–6521.
35. ↵
    1. Frasor J,
    2. Danes JM,
    3. Komm B,
    4. Chang KC,
    5. Lyttle CR &
    6. Katzenellenbogen BS

    2003 Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144 4562–4574.
36. ↵
    1. Frasor J,
    2. Chang EC,
    3. Komm B,
    4. Lin CY,
    5. Vega VB,
    6. Liu ET,
    7. Miller LD,
    8. Smeds J,
    9. Bergh J &
    10. Katzenellenbogen BS

    2006 Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Research 66 7334–7340.
37. ↵
    1. Frønsdal K,
    2. Engedal N,
    3. Slagsvold T &
    4. Saatcioglu F

    1998 CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. Journal of Biological Chemistry 273 31853–31859.
38. ↵
    1. Fullwood MJ &
    2. Ruan Y

    2009 ChIP-based methods for the identification of long-range chromatin interactions. Journal of Cellular Biochemistry 107 30–39.
39. ↵
    1. Garcia-Bassets I,
    2. Kwon YS,
    3. Telese F,
    4. Prefontaine GG,
    5. Hutt KR,
    6. Cheng CS,
    7. Ju BG,
    8. Ohgi KA,
    9. Wang J,
    10. Escoubet-Lozach L
    11. et al.

    2007 Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell 128 505–518.
40. ↵
    1. Gaub MP,
    2. Bellard M,
    3. Scheuer I,
    4. Chambon P &
    5. Sassone-Corsi P

    1990 Activation of the ovalbumin gene by the estrogen receptor involves the fos–jun complex. Cell 63 1267–1276.
41. ↵
    1. Girault I,
    2. Lerebours F,
    3. Amarir S,
    4. Tozlu S,
    5. Tubiana-Hulin M,
    6. Lidereau R &
    7. Bièche I

    2003 Expression analysis of estrogen receptor α coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clinical Cancer Research 9 1259–1266.
42. ↵
    1. Glidewell-Kenney C,
    2. Weiss J,
    3. Lee EJ,
    4. Pillai S,
    5. Ishikawa T,
    6. Ariazi EA &
    7. Jameson JL

    2005 ERE-independent ERα target genes differentially expressed in human breast tumors. Molecular and Cellular Endocrinology 245 53–59.
43. ↵
    1. Gnanapragasam VJ,
    2. Leung HY,
    3. Pulimood AS,
    4. Neal DE &
    5. Robson CN

    2001 Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. British Journal of Cancer 85 1928–1936.
44. ↵
    1. Gräf S,
    2. Nielsen FG,
    3. Kurtz S,
    4. Huynen MA,
    5. Birney E,
    6. Stunnenberg H &
    7. Flicek P

    2007 Optimized design and assessment of whole genome tiling arrays. Bioinformatics 23 i195–i204.
45. ↵
    1. Green S,
    2. Walter P,
    3. Kumar V,
    4. Krust A,
    5. Bornert JM,
    6. Argos P &
    7. Chambon P

    1986 Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320 134–139.
46. ↵
    1. Greene GL,
    2. Gilna P,
    3. Waterfield M,
    4. Baker A,
    5. Hort Y &
    6. Shine J

    1986 Sequence and expression of human estrogen receptor complementary DNA. Science 231 1150–1154.
47. ↵
    1. Hanlon SE &
    2. Lieb JD

    2004 Progress and challenges in profiling the dynamics of chromatin and transcription factor binding with DNA microarrays. Current Opinion in Genetics and Development 14 697–705.
48. ↵
    1. Hayward MA,
    2. Brock ML &
    3. Shapiro DJ

    1982 Activation of vitellogenin gene transcription is a direct response to estrogen in Xenopus laevis liver. Nucleic Acids Research 10 8273–8284.
49. ↵
    1. Hu X &
    2. Lazar MA

    1999 The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402 93–96.
50. ↵
    1. Hu Q,
    2. Kwon YS,
    3. Nunez E,
    4. Cardamone MD,
    5. Hutt KR,
    6. Ohgi KA,
    7. Garcia-Bassets I,
    8. Rose DW,
    9. Glass CK,
    10. Rosenfeld MG
    11. et al.

    2008 Enhancing nuclear receptor-induced transcription requires nuclear motor and LSD1-dependent gene networking in interchromatin granules. PNAS 105 19199–19204.
51. ↵
    1. Hurtado A,
    2. Holmes KA,
    3. Geistlinger TR,
    4. Hutcheson IR,
    5. Nicholson RI,
    6. Brown M,
    7. Jiang J,
    8. Howat WJ,
    9. Ali S &
    10. Carroll JS

    2008 Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456 663–666.
52. ↵
    1. Im JY,
    2. Park H,
    3. Kang KW,
    4. Choi WS &
    5. Kim HS

    2008 Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells. Chemico-Biological Interactions 172 235–244.
53. ↵
    1. Jakowlew SB,
    2. Breathnach R,
    3. Jeltsch JM,
    4. Masiakowski P &
    5. Chambon P

    1984 Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acids Research 12 2861–2878.
54. ↵
    1. Jansen MP,
    2. Foekens JA,
    3. van Staveren IL,
    4. Dirkzwager-Kiel MM,
    5. Ritstier K,
    6. Look MP,
    7. Meijer-van Gelder ME,
    8. Sieuwerts AM,
    9. Portengen H,
    10. Dorssers LC
    11. et al.

    2005 Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. Journal of Clinical Oncology 23 732–740.
55. ↵
    1. Jensen EV,
    2. Block GE,
    3. Smith S,
    4. Kyser K &
    5. DeSombre ER

    1971 Estrogen receptors and breast cancer response to adrenalectomy. National Cancer Institute Monograph 34 55–70.
56. ↵
    1. Jenuwein T &
    2. Allis CD

    2001 Translating the histone code. Science 293 1074–1080.
57. ↵
    1. Jin VX,
    2. Leu YW,
    3. Liyanarachchi S,
    4. Sun H,
    5. Fan M,
    6. Nephew KP,
    7. Huang TH &
    8. Davuluri RV

    2004 Identifying estrogen receptor α target genes using integrated computational genomics and chromatin immunoprecipitation microarray. Nucleic Acids Research 32 6627–6635.
58. ↵
    1. John S,
    2. Sabo PJ,
    3. Johnson TA,
    4. Sung MH,
    5. Biddie SC,
    6. Lightman SL,
    7. Voss TC,
    8. Davis SR,
    9. Meltzer PS,
    10. Stamatoyannopoulos JA
    11. et al.

    2008 Interaction of the glucocorticoid receptor with the chromatin landscape. Molecular Cell 29 611–624.
59. ↵
    1. Jost JP,
    2. Seldran M &
    3. Geiser M

    1984 Preferential binding of estrogen-receptor complex to a region containing the estrogen-dependent hypomethylation site preceding the chicken vitellogenin II gene. PNAS 81 429–433.
60. ↵
    1. Ju BG,
    2. Lunyak VV,
    3. Perissi V,
    4. Garcia-Bassets I,
    5. Rose DW,
    6. Glass CK &
    7. Rosenfeld MG

    2006 A topoisomerase IIβ-mediated dsDNA break required for regulated transcription. Science 312 1798–1802.
61. ↵
    1. Kaczynski J,
    2. Cook T &
    3. Urrutia R

    2003 Sp1- and Krüppel-like transcription factors. Genome Biology 4 206.
62. ↵
    1. Kalaitzidis D &
    2. Gilmore TD

    2005 Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends in Endocrinology and Metabolism 16 46–52.
63. ↵
    1. Kamei Y,
    2. Xu L,
    3. Heinzel T,
    4. Torchia J,
    5. Kurokawa R,
    6. Gloss B,
    7. Lin SC,
    8. Heyman RA,
    9. Rose DW,
    10. Glass CK
    11. et al.

    1996 A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85 403–414.
64. ↵
    1. Kangaspeska S,
    2. Stride B,
    3. Métivier R,
    4. Polycarpou-Schwarz M,
    5. Ibberson D,
    6. Carmouche RP,
    7. Benes V,
    8. Gannon F &
    9. Reid G

    2008 Transient cyclical methylation of promoter DNA. Nature 452 112–115.
65. ↵
    1. Katzenellenbogen BS

    1996 Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biology of Reproduction 54 287–293.
66. ↵
    1. Kininis M,
    2. Chen BS,
    3. Diehl AG,
    4. Isaacs GD,
    5. Zhang T,
    6. Siepel AC,
    7. Clark AG &
    8. Kraus WL

    2007 Genomic analyses of transcription factor binding, histone acetylation, and gene expression reveal mechanistically distinct classes of estrogen-regulated promoters. Molecular and Cellular Biology 27 5090–5104.
67. ↵
    1. Klein-Hitpass L,
    2. Schorpp M,
    3. Wagner U &
    4. Ryffel GU

    1986 An estrogen-responsive element derived from the 5′ flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell 46 1053–1061.
68. ↵
    1. Klinge CM

    2000 Estrogen receptor interaction with co-activators and co-repressors. Steroid 65 227–251.
69. ↵
    1. Kok M,
    2. Linn SC,
    3. Van Laar RK,
    4. Jansen MP,
    5. van den Berg TM,
    6. Delahaye LJ,
    7. Glas AM,
    8. Peterse JL,
    9. Hauptmann M,
    10. Foekens JA
    11. et al.

    2009 Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen. Breast Cancer Research and Treatment 113 275–283.
70. ↵
    1. Krum SA,
    2. Miranda-Carboni GA,
    3. Lupien M,
    4. Eeckhoute J,
    5. Carroll JS &
    6. Brown M

    2008 Unique ERα cistromes control cell type-specific gene regulation. Molecular Endocrinology 22 2393–2406.
71. ↵
    1. Kumar V,
    2. Green S,
    3. Stack G,
    4. Berry M,
    5. Jin JR &
    6. Chambon P

    1987 Functional domains of the human estrogen receptor. Cell 51 941–951.
72. ↵
    1. Kurebayashi J,
    2. Otsuki T,
    3. Kunisue H,
    4. Tanaka K,
    5. Yamamoto S &
    6. Sonoo H

    2000 Expression levels of estrogen receptor-α, estrogen receptor-β, coactivators, and corepressors in breast cancer. Clinical Cancer Research 6 512–518.
73. ↵
    1. Kwon YS,
    2. Garcia-Bassets I,
    3. Hutt KR,
    4. Cheng CS,
    5. Jin M,
    6. Liu D,
    7. Benner C,
    8. Wang D,
    9. Ye Z,
    10. Bibikova M
    11. et al.

    2007 Sensitive ChIP-DSL technology reveals an extensive estrogen receptor α-binding program on human gene promoters. PNAS 104 4852–4857.
74. ↵
    1. Labhart P,
    2. Karmakar S,
    3. Salicru EM,
    4. Egan BS,
    5. Alexiadis V,
    6. O'Malley BW &
    7. Smith CL

    2005 Identification of target genes in breast cancer cells directly regulated by the SRC-3/AIB1 coactivator. PNAS 102 1339–1344.
75. ↵
    1. Laganière J,
    2. Deblois G,
    3. Lefebvre C,
    4. Bataille AR,
    5. Robert F &
    6. Giguère V

    2005 From the cover: location analysis of estrogen receptor α target promoters reveals that FOXA1 defines a domain of the estrogen response. PNAS 102 11651–11656.
76. ↵
    1. Lai EC,
    2. Riser ME &
    3. O'Malley BW

    1983 Regulated expression of the chicken ovalbumin gene in a human estrogen-responsive cell line. Journal of Biological Chemistry 258 12693–12701.
77. ↵
    1. Lin CY,
    2. Ström A,
    3. Vega VB,
    4. Kong SL,
    5. Yeo AL,
    6. Thomsen JS,
    7. Chan WC,
    8. Doray B,
    9. Bangarusamy DK,
    10. Ramasamy A
    11. et al.

    2004 Discovery of estrogen receptor α target genes and response elements in breast tumor cells. Genome Biology 5 R66.
78. ↵
    1. Lin CY,
    2. Vega VB,
    3. Thomsen JS,
    4. Zhang T,
    5. Kong SL,
    6. Xie M,
    7. Chiu KP,
    8. Lipovich L,
    9. Barnett DH,
    10. Stossi F
    11. et al.

    2007 Whole-genome cartography of estrogen receptor α binding sites. PLoS Genetics 3 e87.
79. ↵
    1. Lippman ME,
    2. Rae JM &
    3. Chinnaiyan AM

    2008 An expression signature of estrogen-regulated genes predicts disease-free survival in tamoxifen-treated patients better than progesterone receptor status. Transactions of the American Clinical and Climatological Association 119 77–90.
80. ↵
    1. Liu XF &
    2. Bagchi MK

    2004 Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo. Journal of Biological Chemistry 279 15050–15058.
81. ↵
    1. Liu Y,
    2. Gao H,
    3. Marstrand TT,
    4. Ström A,
    5. Valen E,
    6. Sandelin A,
    7. Gustafsson JA &
    8. Dahlman-Wright K

    2008 The genome landscape of ERα- and ERβ-binding DNA regions. PNAS 105 2604–2609.
82. ↵
    1. Lupien M,
    2. Eeckhoute J,
    3. Meyer CA,
    4. Wang Q,
    5. Zhang Y,
    6. Li W,
    7. Carroll JS,
    8. Liu XS &
    9. Brown M

    2008 FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132 958–970.
83. ↵
    1. Ma H,
    2. Baumann CT,
    3. Li H,
    4. Strahl BD,
    5. Rice R,
    6. Jelinek MA,
    7. Aswad DW,
    8. Allis CD,
    9. Hager GL &
    10. Stallcup MR

    2001 Hormone-dependent, CARM1-directed, arginine-specific methylation of histone H3 on a steroid-regulated promoter. Current Biology 11 1981–1985.
84. ↵
    1. Ma XJ,
    2. Wang Z,
    3. Ryan PD,
    4. Isakoff SJ,
    5. Barmettler A,
    6. Fuller A,
    7. Muir B,
    8. Mohapatra G,
    9. Salunga R,
    10. Tuggle JT
    11. et al.

    2004 A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5 607–616.
85. ↵
    1. Marks H,
    2. Chow JC,
    3. Denissov S,
    4. Françoijs KJ,
    5. Brockdorff N,
    6. Heard E &
    7. Stunnenberg HG

    2009 High-resolution analysis of epigenetic changes associated with X inactivation. Genome Research 19 1361–1373.
86. ↵
    1. Massarweh S,
    2. Osborne CK,
    3. Creighton CJ,
    4. Qin L,
    5. Tsimelzon A,
    6. Huang S,
    7. Weiss H,
    8. Rimawi M &
    9. Schiff R

    2008 Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Research 68 826–833.
87. ↵
    1. McGuire WL

    1973 Estrogen receptors in human breast cancer. Journal of Clinical Investigation 52 73–77.
88. ↵
    1. Métivier R,
    2. Penot G,
    3. Hübner MR,
    4. Reid G,
    5. Brand H,
    6. Kos M &
    7. Gannon F

    2003 Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 115 751–763.
89. ↵
    1. Métivier R,
    2. Gallais R,
    3. Tiffoche C,
    4. Le Péron C,
    5. Jurkowska RZ,
    6. Carmouche RP,
    7. Ibberson D,
    8. Barath P,
    9. Demay F,
    10. Reid G
    11. et al.

    2008 Cyclical DNA methylation of a transcriptionally active promoter. Nature 452 45–50.
90. ↵
    1. Miller TL,
    2. Jin Y,
    3. Sun JM,
    4. Coutts AS,
    5. Murphy LC &
    6. Davie JR

    1996 Analysis of human breast cancer nuclear proteins binding to the promoter elements of the c-myc gene. Journal of Cellular Biochemistry 60 560–571.
91. ↵
    1. Nagalakshmi U,
    2. Wang Z,
    3. Waern K,
    4. Shou C,
    5. Raha D,
    6. Gerstein M &
    7. Snyder M

    2008 The transcriptional landscape of the yeast genome defined by RNA sequencing. Science 320 1344–1349.
92. ↵
    1. Nielsen R,
    2. Pedersen TA,
    3. Hagenbeek D,
    4. Moulos P,
    5. Siersbaek R,
    6. Megens E,
    7. Denissov S,
    8. Børgesen M,
    9. Francoijs KJ,
    10. Mandrup S
    11. et al.

    2008 Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes and Development 22 2953–2967.
93. ↵
    1. Oh DS,
    2. Troester MA,
    3. Usary J,
    4. Hu Z,
    5. He X,
    6. Fan C,
    7. Wu J,
    8. Carey LA &
    9. Perou CM

    2006 Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. Journal of Clinical Oncology 24 1656–1664.
94. ↵
    1. O'Malley BW,
    2. McGuire WL &
    3. Middleton PA

    1968 Altered gene expression during differentiation: population changes in hybridizable RNA after stimulation of the chick oviduct with oestrogen. Nature 218 1249–1251.
95. ↵
    1. Osborne CK,
    2. Hobbs K &
    3. Trent JM

    1987 Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Research and Treatment 9 111–121.
96. ↵
    1. Paik S,
    2. Shak S,
    3. Tang G,
    4. Kim C,
    5. Baker J,
    6. Cronin M,
    7. Baehner FL,
    8. Walker MG,
    9. Watson D,
    10. Park T
    11. et al.

    2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine 351 2817–2826.
97. ↵
    1. Pan YF,
    2. Wansa KD,
    3. Liu MH,
    4. Zhao B,
    5. Hong SZ,
    6. Tan PY,
    7. Lim KS,
    8. Bourque G,
    9. Liu ET &
    10. Cheung E

    2008 Regulation of estrogen receptor-mediated long range transcription via evolutionarily conserved distal response elements. Journal of Biological Chemistry 283 32977–32988.
98. ↵
    1. Perillo B,
    2. Ombra MN,
    3. Bertoni A,
    4. Cuozzo C,
    5. Sacchetti S,
    6. Sasso A,
    7. Chiariotti L,
    8. Malorni A,
    9. Abbondanza C &
    10. Avvedimento EV

    2008 DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science 319 202–206.
99. ↵
    1. Perkins ND,
    2. Felzien LK,
    3. Betts JC,
    4. Leung K,
    5. Beach DH &
    6. Nabel GJ

    1997 Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science 275 523–527.
100. ↵
     1. Petz LN &
     2. Nardulli AM

     2000 Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor a promoter. Molecular Endocrinology 14 972–985.
101. ↵
     1. Pledgie-Tracy A,
     2. Sobolewski MD &
     3. Davidson NE

     2007 Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Molecular Cancer Therapeutics 6 1013–1021.
102. ↵
     1. Pokholok DK,
     2. Harbison CT,
     3. Levine S,
     4. Cole M,
     5. Hannett NM,
     6. Lee TI,
     7. Bell GW,
     8. Walker K,
     9. Rolfe PA,
     10. Herbolsheimer E
     11. et al.

     2005 Genome-wide map of nucleosome acetylation and methylation in yeast. Cell 122 517–527.
103. ↵
     1. Qi C,
     2. Chang J,
     3. Zhu Y,
     4. Yeldandi AV,
     5. Rao SM &
     6. Zhu YJ

     2002 Identification of protein arginine methyltransferase 2 as a coactivator for estrogen receptor α. Journal of Biological Chemistry 277 28624–28630.
104. ↵
     1. Rae JM,
     2. Johnson MD,
     3. Scheys JO,
     4. Cordero KE,
     5. Larios JM &
     6. Lippman ME

     2005 GREB1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Research and Treatment 92 141–149.
105. ↵
     1. Roh TY,
     2. Ngau WC,
     3. Cui K,
     4. Landsman D &
     5. Zhao K

     2004 High-resolution genome-wide mapping of histone modifications. Nature Biotechnology 22 1013–1016.
106. ↵
     1. Rosenfeld MG,
     2. Lunyak VV &
     3. Glass CK

     2006 Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes and Development 20 1405–1428.
107. ↵
     1. Ruff M,
     2. Gangloff M,
     3. Wurtz JM &
     4. Moras D

     2000 Estrogen receptor transcription and transactivation: structure–function relationship in DNA- and ligand-binding domains of estrogen receptors. Breast Cancer Research 2 353–359.
108. ↵
     1. Safe S &
     2. Abdelrahim M

     2005 Sp transcription factor family and its role in cancer. European Journal of Cancer 41 2438–2448.
109. ↵
     1. Savouret JF,
     2. Rauch M,
     3. Redeuilh G,
     4. Sar S,
     5. Chauchereau A,
     6. Woodruff K,
     7. Parker MG &
     8. Milgrom E

     1994 Interplay between estrogens, progestins, retinoic acid and AP-1 on a single regulatory site in the progesterone receptor gene. Journal of Biological Chemistry 269 28955–28962.
110. ↵
     1. Schübeler D,
     2. MacAlpine DM,
     3. Scalzo D,
     4. Wirbelauer C,
     5. Kooperberg C,
     6. van Leeuwen F,
     7. Gottschling DE,
     8. O'Neill LP,
     9. Turner BM,
     10. Delrow J
     11. et al.

     2004 The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes and Development 18 1263–1271.
111. ↵
     1. Schurter BT,
     2. Koh SS,
     3. Chen D,
     4. Bunick GJ,
     5. Harp JM,
     6. Hanson BL,
     7. Henschen-Edman A,
     8. Mackay DR,
     9. Stallcup MR &
     10. Aswad DW

     2001 Methylation of histone H3 by coactivator-associated arginine methyltransferase 1. Biochemistry 40 5747–5756.
112. ↵
     1. Shang Y,
     2. Hu X,
     3. DiRenzo J,
     4. Lazar MA &
     5. Brown M

     2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103 843–852.
113. ↵
     1. Smith CL &
     2. O'Malley BW

     2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocrine Reviews 25 45–71.
114. ↵
     1. Stender JD,
     2. Frasor J,
     3. Komm B,
     4. Chang KC,
     5. Kraus WL &
     6. Katzenellenbogen BS

     2007 Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Molecular Endocrinology 21 2112–2123.
115. ↵
     1. Sultan M,
     2. Schulz MH,
     3. Richard H,
     4. Magen A,
     5. Klingenhoff A,
     6. Scherf M,
     7. Seifert M,
     8. Borodina T,
     9. Soldatov A,
     10. Parkhomchuk D
     11. et al.

     2008 A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome. Science 321 956–960.
116. ↵
     1. Thomas G,
     2. Jacobs KB,
     3. Kraft P,
     4. Yeager M,
     5. Wacholder S,
     6. Cox DG,
     7. Hankinson SE,
     8. Hutchinson A,
     9. Wang Z,
     10. Yu K
     11. et al.

     2009 A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nature Genetics 41 579–584.
117. ↵
     1. Umayahara Y,
     2. Kawamori R,
     3. Watada H,
     4. Imano E,
     5. Iwama N,
     6. Morishima T,
     7. Yamasaki Y,
     8. Kajimoto Y &
     9. Kamada T

     1994 Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. Journal of Biological Chemistry 269 16433–16442.
118. ↵
     1. van't Veer LJ,
     2. Dai H,
     3. van de Vijver MJ,
     4. He YD,
     5. Hart AA,
     6. Mao M,
     7. Peterse HL,
     8. van der Kooy K,
     9. Marton MJ,
     10. Witteveen AT
     11. et al.

     2002 Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 530–536.
119. ↵
     1. Vyhlidal C,
     2. Samudio I,
     3. Kladde MP &
     4. Safe S

     2000 Transcriptional activation of transforming growth factor α by estradiol: requirement for both a GC-rich site and an estrogen response element half-site. Journal of Molecular Endocrinology 24 329–338.
120. ↵
     1. Wagner S,
     2. Weber S,
     3. Kleinschmidt MA,
     4. Nagata K &
     5. Bauer UM

     2006 SET-mediated promoter hypoacetylation is a prerequisite for coactivation of the estrogen-responsive pS2 gene by PRMT1. Journal of Biological Chemistry 281 27242–27250.
121. ↵
     1. Wang HG,
     2. Huang ZQ,
     3. Xia L,
     4. Feng Q,
     5. Erdjument-Bromage H,
     6. Strahl BD,
     7. Briggs SD,
     8. Allis CD,
     9. Wong J,
     10. Tempst P
     11. et al.

     2001 Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science 293 853–857.
122. ↵
     1. Wang Y,
     2. Klijn JG,
     3. Zhang Y,
     4. Sieuwerts AM,
     5. Look MP,
     6. Yang F,
     7. Talantov D,
     8. Timmermans M,
     9. Meijer-van Gelder ME,
     10. Yu J
     11. et al.

     2005 Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365 671–679.
123. ↵
     1. Warner M &
     2. Gustafsson J

     2006 Nongenomic effects of estrogen: why all the uncertainty? Steroids.
124. ↵
     1. Welboren WJ,
     2. van Driel MA,
     3. Janssen-Megens EM,
     4. van Heeringen SJ,
     5. Sweep FCGJ,
     6. Span PN &
     7. Stunnenberg HG

     2009 ChIP-Seq of ERα and RNA polymerase II defines genes differentially responding to ligands. EMBO Journal 28 1418–1428.
125. ↵
     1. Wilhelm BT,
     2. Marguerat S,
     3. Watt S,
     4. Schubert F,
     5. Wood V,
     6. Goodhead I,
     7. Penkett CJ,
     8. Rogers J &
     9. Bähler J

     2008 Dynamic repertoire of a eukaryotic transcriptome surveyed at single-nucleotide resolution. Nature 453 1239–1243.
126. ↵
     1. Wilson IM,
     2. Davies JJ,
     3. Weber M,
     4. Brown CJ,
     5. Alvarez CE,
     6. MacAulay C,
     7. Schübeler D &
     8. Lam WL

     2006 Epigenomics: mapping the methylome. Cell Cycle 5 155–158.
127. ↵
     1. Wu J,
     2. Smith LT,
     3. Plass C &
     4. Huang TH

     2006 ChIP-chip comes of age for genome-wide functional analysis. Cancer Research 66 6899–6902.
128. ↵
     1. Yao TP,
     2. Oh SP,
     3. Fuchs M,
     4. Zhou ND,
     5. Ch'ng LE,
     6. Newsome D,
     7. Bronson RT,
     8. Li E,
     9. Livingston DM &
     10. Eckner R

     1998 Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93 361–372.
129. ↵
     1. Zhang Y,
     2. Sieuwerts AM,
     3. McGreevy M,
     4. Casey G,
     5. Cufer T,
     6. Paradiso A,
     7. Harbeck N,
     8. Span PN,
     9. Hicks DG,
     10. Crowe J
     11. et al.

     2009 The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Research and Treatment 116 303–309.
130. ↵
     1. Zhao Z,
     2. Tavoosidana G,
     3. Sjölinder M,
     4. Göndör A,
     5. Mariano P,
     6. Wang S,
     7. Kanduri C,
     8. Lezcano M,
     9. Sandhu KS,
     10. Singh U
     11. et al.

     2006 Circular chromosome conformation capture (4C) uncovers extensive networks of epigenetically regulated intra- and interchromosomal interactions. Nature Genetics 38 1341–1347.
131. ↵
     1. Zheng W,
     2. Long J,
     3. Gao YT,
     4. Li C,
     5. Zheng Y,
     6. Xiang YB,
     7. Wen W,
     8. Levy S,
     9. Deming SL,
     10. Haines JL
     11. et al.

     2009 Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nature Genetics 41 324–328.